Ideaya biosciences, inc. (IDYA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities
Net loss

-12,043

-10,781

-10,969

-10,656

-9,569

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

336

330

324

298

293

Net amortization of premiums and discounts on marketable securities

-5

22

61

154

236

Stock-based compensation

758

719

518

548

383

Loss on sale of property and equipment

-2

0

-11

0

-3

Gain on sales of marketable securities

2

1

0

6

1

Changes in assets and liabilities
Prepaid expenses and other assets

-1,097

-108

328

1,592

151

Right-of-use assets

-229

-223

-266

-348

-256

Accounts payable

-36

-42

36

-431

242

Accrued and other liabilities

384

1,030

55

1,672

-727

Lease liabilities

-275

-270

-402

-299

-278

Net cash used in operating activities

-9,545

-8,706

-10,550

-10,272

-9,785

Cash flows from investing activities
Purchases of property and equipment, net

-

216

82

449

606

Purchases of marketable securities

11,253

1,887

47,659

19,132

19,326

Maturities of marketable securities

22,159

5,990

49,444

-21,246

39,340

Sales of marketable securities

-

0

-40,144

52,238

6,000

Net cash provided by investing activities

10,906

3,887

-38,441

11,411

25,408

Cash flows from financing activities
Proceeds from exercise of common stock options

34

38

184

66

1

Payments of deferred offering costs

-

-

-

-

827

Net cash provided by (used in) financing activities

34

38

-276

51,674

-826

Net increase in cash, cash equivalents and restricted cash

1,395

-4,781

-49,267

52,813

14,797

Supplemental disclosure of cash flow information:
Cash paid for income taxes

1

0

0

0

1

Cash paid for interest

21

22

45

0

24

Supplemental non-cash investing and financing activities:
Unpaid deferred offering costs

-

-

-

88

375

Vesting of early exercised options and restricted stock

16

26

17

-3

74

Purchases of property and equipment in accounts payable and accrued liabilities

33

-

-31

-439

481